Cargando…

IFN-α/β Signaling Is Required for CDG-Mediated CTL Generation and B Lymphocyte Activation

Among cyclic di-nucleotides (CDN), both cyclic di-AMP (CDA) and di-GMP (CDG) are promising adjuvants and immune modulators. These molecules are not only able to induce profuse antibody production but also predominant T helper 1 and cytotoxic CD8 T lymphocytes (CTL) responses, which enable their use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamouda, Ahmed E. I., Schulze, Kai, Ebensen, Thomas, Guzmán, Carlos Alberto, Lirussi, Darío
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786310/ https://www.ncbi.nlm.nih.gov/pubmed/36559314 http://dx.doi.org/10.3390/pharmaceutics14122821

Ejemplares similares

Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway
por: Lirussi, Darío, et al.
Publicado: (2017)

CDG – an update
por: Morava, Eva, et al.
Publicado: (2011)

Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction
por: Muthuswamy, Ravikumar, et al.
Publicado: (2015)

Cyclic Di-Adenosine Monophosphate: A Promising Adjuvant Candidate for the Development of Neonatal Vaccines
por: Lirussi, Darío, et al.
Publicado: (2021)

SRD5A3-CDG: Emerging Phenotypic Features of an Ultrarare CDG Subtype
por: Kamarus Jaman, Nazreen, et al.
Publicado: (2021)

Peptide-independent Recognition by Alloreactive Cytotoxic T Lymphocytes (CTL)
por: Smith, Pamela A., et al.
Publicado: (1997)

Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL
Publicado: (1996)

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
por: Gandhi, Shipra, et al.
Publicado: (2023)

Selective affinity fractionation of murine cytotoxic T lymphocytes (CTL). Unique lectin specific binding of the CTL associated surface glycoprotein, T 145
Publicado: (1979)

CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)

Mannose supplementation in PMM2-CDG
por: Taday, Roman, et al.
Publicado: (2021)

A novel mutation and first report of dilated cardiomyopathy in ALG6-CDG (CDG-Ic): a case report
por: Al-Owain, Mohammed, et al.
Publicado: (2010)

Spontaneous improvement of carbohydrate-deficient transferrin in PMM2-CDG without mannose observed in CDG natural history study
por: Witters, Peter, et al.
Publicado: (2021)

COG5-CDG: expanding the clinical spectrum
por: Rymen, Daisy, et al.
Publicado: (2012)

Clinical and Molecular Characterization of ALG1-CDG
por: Dhamija, Radhika, et al.
Publicado: (2016)

Nutritional Therapies in Congenital Disorders of Glycosylation (CDG)
por: Witters, Peter, et al.
Publicado: (2017)

L-Fucose treatment of FUT8-CDG
por: Park, Julien H., et al.
Publicado: (2020)

Anthropometric Phenotype of Patients with PMM2-CDG
por: Lipiński, Patryk, et al.
Publicado: (2021)

Genotype-Phenotype Correlations in PMM2-CDG
por: Vaes, Laurien, et al.
Publicado: (2021)

Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease
por: Fox, Lindsey E., et al.
Publicado: (2020)

Virus Replication Strategies and the Critical CTL Numbers Required for the Control of Infection
por: Yates, Andrew J., et al.
Publicado: (2011)

The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization
por: Ebensen, Thomas, et al.
Publicado: (2019)

Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients
por: Maeda, Y, et al.
Publicado: (2002)

Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes
Publicado: (1992)

1α,25(OH)(2) Vitamin D3 Modulates Avian T Lymphocyte Functions without Inducing CTL Unresponsiveness
por: Boodhoo, Nitish, et al.
Publicado: (2016)

Differential regulation of IFNα, IFNβ and IFNε gene expression in human cervical epithelial cells
por: Couret, Jennifer, et al.
Publicado: (2017)

Correction: COG5-CDG: expanding the clinical spectrum
por: Rymen, Daisy, et al.
Publicado: (2013)

ALG8-CDG: novel patients and review of the literature
por: Höck, Michaela, et al.
Publicado: (2015)

ORAL D-GALACTOSE SUPPLEMENTATION IN PGM1-CDG
por: Wong, Sunnie Yan-Wai, et al.
Publicado: (2017)

SLC37A4‐CDG: Second patient
por: Wilson, Matthew P., et al.
Publicado: (2021)

NANS-CDG: Delineation of the Genetic, Biochemical, and Clinical Spectrum
por: den Hollander, Bibiche, et al.
Publicado: (2021)

COG6‐CDG: Novel variants and novel malformation
por: Cirnigliaro, Lara, et al.
Publicado: (2022)

Congenital disorders of glycosylation (CDG): state of the art in 2022
por: Francisco, Rita, et al.
Publicado: (2023)

Drosophila models of PIGA-CDG mirror patient phenotypes
por: Thorpe, Holly J., et al.
Publicado: (2023)

An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease
Publicado: (1994)

Targeting of HIV-1 Antigens for Rapid Intracellular Degradation Enhances Cytotoxic T Lymphocyte (CTL) Recognition and the Induction of De Novo CTL Responses In Vivo After Immunization
por: Tobery, Timothy W., et al.
Publicado: (1997)

Residue analysis of a CTL epitope of SARS-CoV spike protein by IFN-gamma production and bioinformatics prediction
por: Huang, Jun, et al.
Publicado: (2012)

CTL mobilization to virus-infected tissue requires CD4(+) T cell help
por: Nakanishi, Yusuke, et al.
Publicado: (2009)

Variable Fitness Impact of HIV-1 Escape Mutations to Cytotoxic T Lymphocyte (CTL) Response
por: Troyer, Ryan M., et al.
Publicado: (2009)

ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials
por: Malyguine, Anatoli M., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_es4clhm90a2eg3np0l0rpa538d